Ask The Doctors: May 2010

Analysis of data from a large trial has suggested that there is a slightly increased risk of blood clot formation in the veins, or venous thromboembolism (VTE), in patients taking raloxifene compared to those on placebo. The risk for fatal stroke appears somewhat higher, as well. However, the overall risk of these events is still extremely low. Active smoking was the only cardiovascular risk factor which could be tied to increased chance of fatal stroke while taking raloxifene.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access